SIR-Disturbance of the serotonergic system has been suggested as a factor in the pathogenesis of affective disorders. Tryptophan hydroxylase (TPH) is the ratelimiting enzyme in the serotonin biosynthetic pathway and plays an important role in the regulation of serotonin function. Until recently, only one TPH isoform was reported for vertebrates. By targeted ablation of this TPH gene in mice, Walther et al 1 discovered a new brain-specific TPH isoform, called TPH2. The gene encoding this isoform is located on the long arm of chromosome 12 that has been reported as a probable region for bipolar and major depressive disorder (MDD) susceptibility genes. [2] [3] [4] [5] In a recent issue of Molecular Psychiatry, Zill et al 6 reported SNP and haplotype association studies between the TPH2 gene and MDD. They used a case/control sample of 300 MDD individuals and 265 healthy diagnosed controls, and genotyped 10 SNPs covering approximately 28 kb between exons 5 and 7 of this gene. They found positive associations in both single-SNP (intronic SNP rs1386494, P ¼ 0.0012) and haplotype (global P ¼ 0.0001) tests.
Considering our previous linkage studies that pointed to two major bipolar disorder (BP) susceptibility loci, 2 including one at 12q21 (D12S82, NPL Z-all score ¼ 3.92, Po0.01), we also investigated the TPH2 gene as a putative candidate gene using a SNPbased association study on a case/control sample. We ascertained 213 individuals from the Saguenay-LacSt-Jean region of Quebec (bipolar I, n ¼ 182; bipolar II, n ¼ 31). Control individuals (n ¼ 214) were selected among other genetic studies, ethnically matched with the case group, but without diagnosis of psychiatric history, since there is no real gain in power to diagnose controls for a disease such as BP that has a lifetime risk of around 1%. 7 The analyzed SNPs were selected following a mutation screening in 16 BP individuals on all TPH2 exons and exon-intron junctions covering 5.2 kb of the genomic sequence, which were more likely to disturb protein function. Since we did not detect any polymorphism affecting the amino-acid sequence, we analyzed all the five identified SNPs, two of which were synonymous coding SNPs (TPH2E07A, TPH2E09A), and were distributed over 24 kb between exons 7 and 9 of the TPH2 gene (Table 1 ). All SNPs were located downstream of the SNP analyzed by Zill et al.
The association hypothesis was tested using CLUMPv1.6, and neither allelic nor genotypic association with BP was observed for any individual SNP (PZ0.06). However, haplotype analysis, which has been performed with the cocaphase program from the UNPHASE package version 2.40, 8 demonstrated a significant association at the 5% threshold level, P ¼ 0.0317 (Table 2) . We observed more haplotype heterogeneity than previously noted by Zill. Five out of our eight estimated haplotypes represent 90 and 93% of haplotypes found in case and control groups, respectively.
The SNPs we analyzed overlap the region analyzed by Zill et al and our data give support to their results that suggest the existence of an affective disorderassociated haplotype in the TPH2 gene. However, the absence of potentially functional SNPs in both studies strongly suggests that polymorphisms in both TPH2 regulatory regions and adjacent genes need to be investigated.
Family and twin studies indicate that BP and MDD share common genetic components. 9 Considering )  40237  rs7305115  TPH2I07A  C-T  55467  -TPH2I08A  G-T  55749  rs1007023  TPH2I08B  A-G  83369  -TPH2E09A A-T(A375A) 83610 rs4290270
The position is given relative to the 5 0 -end of TPH2 in contig NT_029419.10 from the NCBI. The dbSNP reference number is given if present. such a hypothesis, the sampling strategy (undiagnosed controls) could have reduced the power of our case/control analysis since major depression demonstrates a prevalence of 5-17%. Accordingly, this could partially explain the modest haplotypic association. In conclusion, owing to the potential role of TPH in affective disorders, and the restricted expression of the TPH2 isoform in brain, the results reported, together with those of Zill et al, clearly show the need for further investigations.
Failure to confirm association between AKT1 haplotype and schizophrenia in a Japanese case-control population SIR-AKT1 is a serine/threonine kinase known as protein kinase B. Modulation of AKT1 activity appears to play a key role in the mechanism of glutamate excitotoxicity and lithium neuroprotection. 1 Glycogen synthase kinase 3b (GSK3b) is one of the substrates of AKT1 and AKT1/GSK3b signaling is known as a target of lithium. Lithium can exert its acute effect on dopamine-dependent behaviors by interfering with the action of dopamine on an Akt/ GSK-3 signaling cascade in the brain of living mice. 2 Transmission of haplotypes construct from seven single-nucleotide polymorphisms (SNPs) in a highly variable region of the AKT1 gene has been shown to have a weak evidence of association with bipolar disorder. 3 Recently, Emamian et al 4 identified AKT1 as a potential schizophrenia susceptibility gene in families of northern European origin. Levels of the AKT1 protein and phosphorylation of GSK3b at Ser9 in lymphocytes and frontal cortex were significantly lower in patients with schizophrenia in comparison with the controls. Moreover, AKT1-deficient mice treated with amphetamine show reduced prepulse inhibition (PPI). The impairment of PPI has been observed in patients with schizophrenia. Haloperidol-treated mice show increased phosphorylation of GSK3b at Ser9. In multi-SNP haplotype analysis, haplotypes containing two to five SNPs (SNP1-5) in the AKT1 gene were associated with schizophrenia. The TCG haplotype consisting of three SNPs (SNP2/ 3/4) showed the highest significant association with schizophrenia (ratio of transmission to no transmission ¼ 1.8, P ¼ 0.0006). The AKT1 core risk haplotype TC of the SNP2/3 is associated with lower AKT1 protein levels.
We attempted to confirm the association of AKT1 haplotype with schizophrenia in Japanese subjects comprising of 559 patients with schizophrenia and 567 controls. All subjects were unrelated. The TCG haplotype was estimated to confer a relative risk of 1.9 in the study by Emamian et al. 4 Our sample size has 0.999 power to detect the association at the haplotype frequency of 0.085, which was observed in our Japanese control subjects, at a nominal significance level of 5%.
The patients with schizophrenia analyzed were 559 unrelated Japanese (320 men, 239 women; age 18-90 years, mean 49.5 years). Diagnoses were determined after unstructured clinical interviews, and final diagnoses were carried out by consensus of at least two psychiatrists. All subjects met DSM-III-R criteria for schizophrenia. The control subjects consisted of 567 unrelated Japanese individuals (390 men, 177 women; age 29-77 years, mean 51.6 years). Control subjects were not evaluated by psychiatrists. Written informed consent was obtained from all subjects. This study was approved by the Ethics Committees of University of Tsukuba, Tokyo Medical and Dental University, the National Center of Neurology and Psychiatry, and Nagoya University. We examined the population structure with Structure software (http:// pritch.bsd.uchicago.edu/) 5 to rule out the possibility that the difference in a case-control study was influenced by hidden population stratification. We genotyped 32 markers (seven microsatellite markers and 25 SNPs) and observed no subpopulation using the number of assumed subpopulation k ¼ 2 and 3 (data not shown).
The ID numbers of these five SNPs were provided by Emamian et al. 4 All SNPs were genotyped with Taqman s Assays-by-Design SM SNP Genotyping Service (Applied Biosystems) 6 and ABI PRISM s 7900HT Sequence Detection System (Applied Biosystems).
